Press release
Plexiform Neurofibroma Market to Grow at 9.7% CAGR from 2025 to 2034
Plexiform Neurofibroma Market
Rising research in neurofibromatosis type 1 (NF1), FDA approvals of MEK inhibitors, and emerging gene-editing therapies are driving strong global growth in the plexiform neurofibroma market.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72662
Introduction
The Plexiform Neurofibroma Market is entering a period of rapid expansion as precision medicine and genetic therapies reshape the management of neurofibromatosis type 1 (NF1) and related tumor growth disorders.
Valued at USD 410 million in 2024, the market is projected to reach USD 1.02 billion by 2034, growing at a CAGR of 9.7% over the forecast period.
Plexiform neurofibromas are benign nerve sheath tumors associated primarily with NF1, a genetic condition affecting roughly one in 3,000 individuals worldwide. Although non-malignant, these tumors often cause significant morbidity, disfigurement, and pain, making targeted therapies and early diagnosis vital for improved patient outcomes.
Key Players in the Market
The competitive landscape includes major pharmaceutical innovators and biotech firms advancing MEK inhibitors, genetic therapies, and targeted small molecules for NF1-related plexiform neurofibromas.
Key players include:
• AstraZeneca plc
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• SpringWorks Therapeutics Inc.
• Bayer AG
• Aadi Bioscience Inc.
• Genentech Inc.
• Takeda Pharmaceutical Company Ltd.
• GlaxoSmithKline plc (GSK)
These players are expanding research pipelines in MAPK pathway inhibition, tumor growth suppression, and gene-based NF1 correction therapies.
Key Events in the Last Five Years
• 2020: AstraZeneca's Koselugo® (selumetinib) became the first FDA-approved treatment for pediatric patients with inoperable plexiform neurofibromas, marking a landmark shift in care.
• 2022: SpringWorks Therapeutics initiated Phase III trials for mirdametinib, another MEK inhibitor showing strong clinical efficacy and safety in NF1 patients.
• 2023: Novartis announced collaborations focused on next-generation gene therapy for NF1 mutation correction using CRISPR-Cas9 platforms.
• 2024: Increasing use of MRI-based AI imaging tools enhanced tumor volume measurement and treatment-response evaluation in NF1 clinical trials.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72662/plexiform-neurofibroma-market
Market Growth Rate
According to Exactitude Consultancy, the global plexiform neurofibroma market will grow at a CAGR of 9.7% (2025-2034), driven by:
• Expanding MEK inhibitor approvals and access programs.
• Genetic therapy breakthroughs addressing NF1 mutations directly.
• Increased patient awareness and diagnosis through genetic testing initiatives.
• Regulatory incentives and orphan-drug designations for rare-tumor therapeutics.
Market Segments and Growth Analysis
The market is segmented by therapy type, patient group, and region.
By Therapy Type:
• MEK Inhibitors (Selumetinib, Mirdametinib, Trametinib)
• Gene Therapy and RNA-Based Therapies
• mTOR Inhibitors and Targeted Small Molecules
• Supportive and Surgical Management
By Patient Group:
• Pediatric (Children and Adolescents)
• Adult
By Region:
• North America: Dominates due to strong NF1 research infrastructure and early adoption of MEK inhibitor therapies.
• Europe: Expanding clinical trials and EMA orphan-drug approvals boost regional growth.
• Asia Pacific: Increasing genetic testing and pharmaceutical investment in Japan, India, and South Korea drive awareness and diagnosis.
• Latin America & MEA: Gradual increase in rare-disease programs and NF1 support initiatives.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72662
Key Market Drivers
1. Precision Targeted Therapies:
MEK inhibitors have demonstrated sustained tumor shrinkage and symptom improvement in NF1 patients.
2. Advances in Genetic and RNA Therapies:
CRISPR-based and siRNA therapeutics are emerging to correct or silence NF1 mutations at the molecular level.
3. Rising Awareness and Screening:
Early detection through genetic panels and family counseling increases the treated patient pool.
4. Government and NGO Support:
Expanded rare-disease funding programs and patient advocacy groups are accelerating diagnosis and treatment access.
Recent Developments
• 2023: SpringWorks Therapeutics reported positive Phase III results for mirdametinib, showing significant tumor shrinkage and pain reduction.
• 2024: Roche and Genentech began joint research on combination therapies targeting both MAPK and PI3K pathways.
• 2024: Pfizer announced investment in AI-powered tumor monitoring solutions for NF1 patients using deep-learning imaging analytics.
• 2024: Bayer advanced pre-clinical NF1 gene-repair studies in collaboration with academic institutes in Germany and the U.S.
Expert Insight
"Plexiform neurofibroma treatment has entered a transformative phase. MEK inhibitors have proven that targeted therapy works, and the next frontier lies in gene-correction technologies that may deliver lasting remission,"
- Dr. Hannah McGregor, Neuro-Oncology Specialist, Mayo Clinic.
Conclusion
The Plexiform Neurofibroma Market is progressing from symptomatic care to disease-modifying treatment.
With breakthroughs in MEK inhibition, RNA-based therapies, and gene editing, the outlook for NF1 patients has never been brighter.
As clinical trials expand globally and AI technologies enhance diagnostic precision, the next decade will see this once-rare market evolve into a key segment of the neuro-oncology and genetic-therapy ecosystem.
This report is also available in the following languages : Japanese (叢状神経線維腫市場), Korean (총상 신경섬유종 시장), Chinese (丛状神经纤维瘤市场), French (Marché des neurofibromes plexiformes), German (Markt für plexiforme Neurofibrome), and Italian (Mercato del neurofibroma plessiforme), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72662
Our More Reports:
Mantle Cell Lymphoma Market
https://exactitudeconsultancy.com/reports/72262/mantle-cell-lymphoma-market
Scleritis Market
https://exactitudeconsultancy.com/reports/72281/scleritis-market
Persistent Epithelial Defect Market
https://exactitudeconsultancy.com/reports/72290/persistent-epithelial-defect-market
Uveitis Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72310/uveitis-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plexiform Neurofibroma Market to Grow at 9.7% CAGR from 2025 to 2034 here
News-ID: 4257390 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for NF1
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% duri …
Market Overview
The Neurofibromatosis Type 1 (NF1) market is undergoing a major transformation fueled by advancements in precision oncology, genetic diagnostics, and targeted therapies. NF1 is a common autosomal dominant disorder characterized by café-au-lait spots, plexiform neurofibromas, cutaneous neurofibromas, optic pathway gliomas, skeletal abnormalities, and increased tumor predisposition.
The global market for NF1-related therapies and associated tumor management was valued at an estimated USD 340-440 million in 2024. As novel targeted treatments…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
